High-affinity anti-B7-H3 monoclonal antibody and application thereof

By developing high-affinity anti-B7-H3 monoclonal antibodies, the problem of insufficient binding of existing antibodies to B7-H3 antigen and endocytosis activity in B7-H3 was solved, and high-affinity binding and strong endocytosis activity in B7-H3 was achieved, making it a tumor Treatment provides new antibody molecules.

CN118894935APending Publication Date: 2024-11-05BIOSION INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310490891.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing B7-H3 targeting antibodies do not yet have good B7-H3 antigen binding ability and antibody endocytosis activity, and cannot be effectively used in tumor treatment.

Method used

A high-affinity anti-B7-H3 monoclonal antibody was developed, containing specific heavy and light chain variable region amino acid sequences, with high human B7-H3 affinity and antibody endocytosis activity, through hybridoma technology and recombinant DNA Technical preparation.

Benefits of technology

It achieved high affinity binding to human B7-H3 and strong endocytosis activity, providing candidate antibody molecules for the development of anti-tumor drugs, with stronger human B7-H3 binding activity and higher cynomolgus monkey B7- H3 binding capability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894935A_ABST
    Figure CN118894935A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, particularly relates to a high-affinity anti-B7-H3 monoclonal antibody and application thereof, provides a coding nucleic acid molecule, an expression vector and a host cell of the antibody and a method for expressing the antibody, and further provides a pharmaceutical composition containing the antibody and application. The affinity of the high-affinity anti-B7-H3 monoclonal antibody and human B7-H3 is higher than that of a reference antibody, meanwhile, the high-affinity anti-B7-H3 monoclonal antibody has high antibody endocytosis activity, is novel in sequence and is a novel anti-B7-H3 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a high-affinity anti-B7-H3 monoclonal antibody and a use thereof. Background Art

[0002] B7-H3 (also known as CD276) is a member of the B7 superfamily and is a protein with a unidirectional transmembrane structure, which includes an amino-terminal signal peptide, an immunoglobulin-like variable region, a constant region, a transmembrane region, and an intracellular region.

[0003] In the early stages of research, B7-H3 was primarily viewed as a co-stimulatory receptor that promotes CD4 + and CD8 + The proliferation of T cells, enhance the activity of cytotoxic T lymphocytes, and selectively stimulate IFN-γ to produce immunostimulatory functions under the condition of TCR signaling. As the research deepens, more evidence shows that B7-H3 mainly plays a co-inhibitory role in immune cells, which helps tumor cells escape immune surveillance (Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol, 2001, 2 (3): 269-274.).

[0004] B7-H3 protein is expressed in limited amounts in normal tissues, but is abnormally expressed in a variety of malignant tumors, and overexpression of B7-H3 is associated with poor prognosis of tumor patients, tumor invasion and migration. For example, in patients with hepatocellular carcinoma, CD14 in the liver is significantly higher than in the peripheral blood. + HLA-DR hi Macrophages, CD14 + HLA-DR low / -The expression of B7-H3 is upregulated on monocyte bone marrow-derived suppressor cells and myeloid dendritic cells, and the expression of B7-H3 in tumor antigen-presenting cells is even higher than that in normal liver or adjacent tumor areas (Lee Y, Martin-Orozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res, 2017, 27(8): 1034-1045.). In addition, B7-H3 can also promote angiogenesis in clear cell renal cell carcinoma through the tyrosine kinase receptor Tie-2 pathway, or promote the invasion and metastasis of pancreatic cancer cells through the TLR4 / NF-κB pathway (Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci, 2020, 16(11): 1767-1773.).

[0005] Loss of B7-H3 significantly reduced the infiltration of regulatory T cells, CD8 + The function of T cells was enhanced, and the secretion of TNF-α and IFN-γ increased. In addition, the survival and median survival of tumor-bearing mice were significantly prolonged after treatment with anti-B7-H3 antibodies (Cai D, Li J, Liu D, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1blockade therapy. Cell Mol Immunol, 2020, 17(3): 227-

[0006] 236.), indicating that blocking the signal transduction of B7-H3 can be used for tumor treatment. And because there are significant differences in the expression levels of B7-H3 in normal tissues and tumor tissues, tumor cells can be selectively killed through the antibody-dependent cellular cytotoxicity (ADCC) of anti-B7-H3 antibodies or toxin coupling.

[0007] So far, no antibody drugs targeting B7-H3 have been marketed. Enoblituzumab is the first fully humanized anti-B7-H3 monoclonal antibody that contains an immunoglobulin G1 fragment crystallizable (Fc) domain that can enhance the Fcγ receptor-mediated ADCC effect (Aggarwal C, Prawira A, Antonia S, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I / II trial. J Immunother Cancer, 2022, 10(4): e004424.) and is currently in Phase II clinical trials for prostate cancer.

[0008] Therefore, there is a need in the art to develop an anti-B7-H3 antibody, especially an anti-B7-H3 antibody with good B7-H3 antigen binding ability and strong ADCC effect. Summary of the invention

[0009] The purpose of the present invention is to solve the deficiencies of the above prior art and to provide a high-affinity anti-B7-H3 monoclonal antibody and its use. The monoclonal antibody has a high affinity for human B7-H3 and has strong antibody endocytosis activity.

[0010] The present invention provides a high-affinity anti-B7-H3 monoclonal antibody, the antibody comprising a heavy chain variable region and a light chain variable region;

[0011] The heavy chain variable region comprises V H CDR1, V H CDR2 and V H CDR3, the light chain variable region comprises V L CDR1, V L CDR2 and V L CDR3;

[0012] The V H The amino acid sequence of CDR1 is shown in SEQ ID NO: 2;

[0013] The V H The amino acid sequence of CDR2 is shown in SEQ ID NO: 4;

[0014] The V HThe amino acid sequence of CDR3 is shown in SEQ ID NO: 6;

[0015] The V L The amino acid sequence of CDR1 is shown in SEQ ID NO: 12;

[0016] The V L The amino acid sequence of CDR2 is shown in SEQ ID NO: 14;

[0017] The V L The amino acid sequence of CDR3 is shown in SEQ ID NO:16.

[0018] Preferably, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:8; and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:18.

[0019] Preferably, the heavy chain amino acid sequence is shown as SEQ ID NO: 10; and the light chain amino acid sequence is shown as SEQ ID NO: 20.

[0020] Preferably, both the heavy chain and the light chain further include a constant region, which is a constant region of mouse or human IgG, preferably a constant region of IgG1.

[0021] The present invention further provides a nucleotide molecule encoding the above-mentioned high-affinity anti-B7-H3 monoclonal antibody.

[0022] Preferably, the sequence of the nucleotide molecule is selected from SEQ ID NO: 7 and SEQ ID NO: 17;

[0023] The sequence SEQ ID NO: 7 encodes the heavy chain variable region of the antibody;

[0024] The sequence SEQ ID NO: 17 encodes the light chain variable region of the antibody.

[0025] The present invention further provides an expression vector containing the nucleotide molecule.

[0026] The present invention further provides a host cell containing the expression vector.

[0027] Preferably, the host cell is a eukaryotic cell, preferably a mammalian cell.

[0028] The present invention further provides a method for preparing the above-mentioned high-affinity anti-B7-H3 monoclonal antibody, comprising the following steps:

[0029] (1) preparing an expression vector containing a nucleotide molecule encoding the high-affinity anti-B7-H3 monoclonal antibody;

[0030] (2) transfecting eukaryotic host cells with the expression vector obtained in step (1) and culturing the cells;

[0031] (3) Isolation and purification to obtain high-affinity anti-B7-H3 monoclonal antibodies.

[0032] The present invention further provides a bispecific molecule, an antibody immunoconjugate, a chimeric antigen receptor or a pharmaceutical composition comprising the above anti-B7-H3 monoclonal antibody.

[0033] Furthermore, the pharmaceutical composition comprises a therapeutically effective amount of the high-affinity anti-B7-H3 monoclonal antibody, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0034] The present invention further provides the use of the high-affinity anti-B7-H3 monoclonal antibody in the preparation of anti-tumor drugs.

[0035] Preferably, the tumor is a solid tumor or a hematological tumor, including solid tumors such as head and neck cancer, oral cancer, esophageal cancer, gastric cancer, colorectal cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, bladder cancer, melanoma, breast cancer, ovarian cancer, prostate cancer, and hematological malignancies such as acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and diffuse large B-cell lymphoma (DLBCL).

[0036] Beneficial Effects

[0037] Compared with existing anti-B7-H3 monoclonal antibodies, the anti-B7-H3 monoclonal antibodies of the present invention have stronger human B7-H3 affinity and antibody endocytosis activity, and have higher cynomolgus monkey B7-H3 binding activity, providing candidate antibody molecules for the development of antibody drug conjugates (ADCs). BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The affinity of antibody B1F1F9G7 to human B7-H3 protein was determined by BIACORE surface plasmon resonance method;

[0039] Figure 2 Indirect ELISA was used to determine the binding ability of antibody B1F1F9G7 to mouse B7-H3 protein;

[0040] Figure 3 Indirect ELISA was used to determine the binding ability of antibody B1F1F9G7 to cynomolgus monkey B7-H3 protein;

[0041] Figure 4Flow cytometry was used to evaluate the binding ability of antibody B1F1F9G7 to human B7-H3 protein on the cell membrane surface;

[0042] Figure 5 To detect the endocytic activity of the anti-B7-H3 antibody B1F1F9G7. DETAILED DESCRIPTION

[0043] the term

[0044] "Binding to B7-H3" or "binding to B7-H3" means being able to interact with human B7-H3. "Specific binding" means being able to bind to human B7-H3 protein (and possibly B7-H3 protein from one or more non-human species) but not substantially binding to non-B7-H3 proteins.

[0045] "Antigen binding site" refers to one or more fragments of an antibody that have the ability to specifically bind to an antigen (eg, B7-H3 protein).

[0046] "Monoclonal antibody" refers to a preparation of antibody molecules having a single amino acid composition, exhibiting a single binding specificity and affinity for a particular epitope. Monoclonal antibodies or antigen-binding fragments thereof can be prepared, for example, by hybridoma technology, recombinant DNA technology, phage display technology, synthetic technology such as CDR grafting technology, or a combination of such or other techniques known in the art.

[0047] "Affinity" refers to the strength of the sum of all non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, herein, "binding affinity" refers to the intrinsic binding affinity reflecting a 1:1 interaction between an antibody and an antigen. Affinity can be measured by common methods known in the art, including those described in the prior art and herein.

[0048] The term "competition" when used in the context of antigen binding proteins (e.g., neutralizing antigen binding proteins or neutralizing antibodies) competing for the same epitope means competition between antigen binding proteins, which is determined by the following assay: in the assay, the antigen binding protein to be tested (e.g., antibody or immunologically functional fragment thereof) prevents or inhibits (e.g., reduces) the specific binding of a reference antigen binding protein (e.g., ligand or reference antibody) to a common antigen (e.g., B7-H3 or a fragment thereof). Numerous types of competitive binding assays can be used to determine whether one antigen binding protein competes with another. Competitive inhibition is measured by measuring the amount of label bound to a solid surface or cell in the presence of the tested antigen binding protein. Typically, the tested antigen binding protein is present in excess. Antigen binding proteins identified by competitive assays (competing antigen binding proteins) include: antigen binding proteins that bind to the same epitope as the reference antigen binding protein; and antigen binding proteins that bind to adjacent epitopes that are sufficiently close to the binding epitope of the reference antigen binding protein, and the two epitopes sterically hinder each other from binding.

[0049] Methods for producing and purifying antibodies and antigen-binding fragments are well known and disclosed in the prior art, such as the Cold Spring Harbor Guide to Antibody Experimental Technology. For example, mice can be immunized with human B7-H3 or fragments thereof, and the resulting antibodies can be renatured, purified, and amino acid sequenced using conventional methods. Antigen-binding fragments can also be prepared using conventional methods.

[0050] "Treatment" means administering an internal or external therapeutic agent, such as a composition comprising a B7-H3 antibody or an antigen-binding fragment thereof, to a patient who has one or more symptoms of a disease. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in the patient or population being treated, whether by inducing regression of such symptoms or inhibiting the development of such symptoms to any clinically measurable degree. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect on the patient. Whether a disease symptom has been alleviated may be assessed by any clinical test method commonly used by physicians or other health care professionals to assess the severity or progression of the symptom.

[0051] An "effective amount" includes an amount sufficient to improve or prevent the symptoms or symptoms of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the method, route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects.

[0052] "Pharmaceutical composition" refers to a mixture containing one or more B7-H3 antibodies or antigen-binding fragments thereof described herein and other pharmaceutical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0053] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Reagents that do not specify specific sources are conventional reagents purchased from the market.

[0054] Example 1 Obtaining specific anti-B7-H3 mouse monoclonal antibodies by fusion hybridoma technology

[0055] 1.1 Animal immunization

[0056] Mice were immunized according to the common method in the literature (E Harlow, D. Lane, Antibody: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998). The immunogen was recombinant human B7-H3 protein (Sino biological Inc., Cat#11188-H02H).

[0057] In order to increase the immune response, Freund's complete adjuvant and Freund's incomplete adjuvant (Sigma, St. Louis, Mo., USA) were used for the first immunization and the booster immunization, respectively. Briefly, the required amount of adjuvant was first added to a 1.5 mL microcentrifuge tube sterilized by high pressure; the antigen was then prepared in PBS or physiological saline with a concentration of 0.5-1.0 mg / ml; finally, the calculated amount of antigen and adjuvant were added to the microcentrifuge tube, gently vortexed for 2 minutes, and emulsified and mixed repeatedly to form an oil-in-water solution to obtain an adjuvant-antigen mixture. Then, an appropriate amount of the adjuvant-antigen mixture was inhaled with a syringe to inject each animal for immunization. Two to three booster immunizations were performed according to the antiserum titer. Before cell fusion, the animals with better titers were given a final booster immunization by intraperitoneal injection.

[0058] 1.2 Hybridoma fusion and screening

[0059] Cells of mouse myeloma cell line (SP2 / 0-Ag14, ATCC#CRL-1581) were cultured to reach logarithmic growth phase before cell fusion. Immunized mouse spleen cells were prepared in a sterile manner and fused with myeloma cells according to the method described in the literature (Kohler G, and Milstein C, "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 256: 495-497 (1975).).

[0060] The fused "hybrid cells" were then distributed into 96-well cell plates containing DMEM / 20% FCS / HAT medium. Usually, surviving hybridoma cells can be observed growing under a microscope 7-10 days after fusion. Two weeks after cell plating, FACS (flow cytometry) was used to screen B7-H3 binding positive clones. Briefly, the stable cell line 293F, i.e., B7-H3-293F, which overexpresses human B7-H3 on the surface in the logarithmic growth phase, was collected from the cell culture flask (constructed in-house by the company, and the full-length human B7-H3 protein was transfected into 293F cells using 293fectin transfection reagent. The amino acid sequence of expressed B7-H3 is shown in Uniprot Q5ZPR3-2), washed twice, and resuspended in PBS (FACS buffer) containing 2% v / v fetal bovine serum. 1×10 5 Cells / well and the above hybridoma supernatant were incubated on ice for 40 minutes. Washed 3 times with FACS buffer, and continued to add 100 μL / well of R-phycoerythrin affinity purified F(ab')2 fragment goat anti-mouse IgG (H+L) (1:1000 diluted in FACS buffer, Jackson Immunoresearch, Cat#115-116-146). After incubation at 4°C in the dark for 40 minutes, the cells were washed 3 times and then resuspended in FACS buffer. Fluorescence measurement was performed using a Becton Dickinson FACS Canto II-HTS device. Positive hybridomas that secrete antibodies that bind to B7-H3-293F cells were then selected and transferred to 24-well plates.

[0061] The hybridoma clones producing antibodies that bind to human B7-H3 with high specificity were subcloned by limiting dilution to ensure the monoclonal origin of the cell line and then purified. Briefly, the protein A agarose column was washed with 5-10 column volumes of PBS buffer. The cell supernatant of the hybridoma monoclonal antibody was passed through the column and then the column was washed with PBS buffer until the protein absorbance reached the baseline. The column was eluted with elution buffer (0.1M glycine-HCl, pH 2.7) and immediately collected in a 1.5ml tube containing a neutral buffer (1M Tris-HCl, pH 9.0). The immunoglobulin-containing fractions were mixed and dialyzed overnight in PBS at 4°C. Subsequently, the functional activity of the purified monoclonal antibody was characterized in vitro as described below.

[0062] Example 2 Determination of the affinity of mouse anti-B7-H3 monoclonal antibody using BIACORE surface plasmon resonance technology

[0063] The affinity kinetics of the anti-B7-H3 mouse monoclonal antibodies (mAbs) produced by the hybridoma clones in Example 1 were characterized using the Biacore T200 system (GE healthcare, Pittsburgh, PA, USA).

[0064] Enoblituzumab (MacroGenics) was used as a reference antibody (prepared in-house, the heavy chain sequence is shown in SEQ ID NO: 21, and the light chain amino acid sequence is shown in SEQ ID NO: 22).

[0065] Briefly, goat anti-mouse IgG was covalently linked to a CM5 chip (carboxymethyl dextran coated chip) via primary amines using a standard amine coupling kit provided by Biacore. Unreacted groups on the biosensor surface were blocked with ethanolamine. The purified mouse anti-B7-H3 antibody and reference antibody produced in Example 1 were passed through the chip at a concentration of 66.7 nM and a flow rate of 10 μL / min. Then, a 1% dextrose solution prepared in HBS-EP was added to the chip. + Recombinant human B7-H3-his protein (Sino Biological Inc, Cat#11188-H08H) in buffer (provided by Biacore) was flowed through the chip at a flow rate of 30 μL / min. Antigen-antibody binding kinetics were observed for 2 minutes and dissociation kinetics for 10 minutes. The BIAcore evaluation software was used to fit the 1:1 Langmuir binding model. a , k d and K D The values ​​of are shown in Table 1.

[0066] Table 1. Kinetic parameters of mouse anti-B7-H3 monoclonal antibody binding to human B7-H3 determined by Biacore

[0067]

[0068] like Figure 1 As shown in Table 1, the binding K of the monoclonal antibody B1F1F9G7 of the present invention to human B7-H3 D The value is smaller than that of the reference antibody, indicating that it has a stronger affinity for human B7-H3.

[0069] Example 3 Study on Binding Activity of Mouse Anti-B7-H3 Monoclonal Antibodies

[0070] The mouse anti-B7-H3 monoclonal antibody produced by the hybridoma clones in Example 1 was further tested for its binding activity using the following method.

[0071] 3.1 Determination of antibody binding capacity based on indirect ELSIA

[0072] The cross-reactivity of B7-H3 antibodies with mouse B7-H3 protein and cynomolgus monkey B7-H3 protein was tested.

[0073] Briefly, 100 μl / well of 2 μg / ml mouse B7-H3-his (Acrobiosystems, Cat#B73-M52H4, MW: 25.4 kDa) or 2 μg / ml cynomolgus monkey B7-H3-his (Acro biosystems, Cat#B73-C52Ha, MW: 49.0 kDa) was added to a 96-well ELISA plate and incubated for 2 h at 37° C. The plate was washed once with PBST (PBS + 0.05% Tween-20) and blocked with 200 μl of blocking buffer (PBST containing 5% w / v skim milk) at 37° C. for 2 h. The plate was washed again and incubated with 100 μl / well of serially diluted anti-B7-H3 antibody or control antibody (starting from 66.7 nM, 5-fold serial dilution in PBST containing 2.5% skim milk powder) at 37° C. for 2 h. The ELISA plate was washed 4 times, and 100 μl / well of peroxidase affinity purified goat anti-mouse IgG, Fcγ fragment specific (Jackson ImmunoResearch Laboratories Inc., Cat#115-035-071) or peroxidase affinity purified F(ab')2 fragment goat anti-human IgG, Fcγ fragment specific (Cat#109-036-098, Jackson ImmunoResearch Laboratories Inc.) was added thereto, and incubated at 37°C for 40 minutes. After the final wash, 100 μl / well of TMB (Cat#TMB-S-002, Innoreagents) was added to react at room temperature for 40 minutes. The reaction was then terminated with 1M H2SO4, and the absorbance at 450-630nm was measured. The data were analyzed using Graphpad Prism software to obtain the EC 50 For specific results, see Figure 2 and Figure 3 .

[0074] The results showed that the antibody B1F1F9G7 of the present invention did not bind to mouse B7-H3, but bound to cynomolgus monkey B7-H3 and had an EC equivalent to that of the reference antibody. 50 Value and Bmax (maximum binding).

[0075] 3.2 Flow cytometry (FACS) determination of the binding of anti-B7-H3 monoclonal antibodies to 293F cell lines overexpressing human B7-H3 on their surface

[0076] The stable cell line 293F overexpressing human B7-H3 on its surface was collected from the cell culture flask, washed twice, and resuspended in PBS (FACS buffer) containing 2% v / v fetal bovine serum. 1.5×10 5Cells / well and different concentrations of B7-H3 antibody or reference antibody (starting from 66.7nM, 5-fold serial dilution) in FACS buffer were incubated on ice for 40 minutes. Wash with FACS buffer 3 times, and continue to add 100μL / well of R-phycoerythrin affinity purified F(ab')2 fragment goat anti-mouse IgG (H+L) or R-phycoerythrin affinity purified goat anti-human IgG, Fcγ fragment specific (Cat#115-116-146 or Cat#109-115-098, Jackson Immunoresearch Laboratories, Inc.,) (1:1000 dilution in FACS buffer). After incubation at 4°C in the dark for 40 minutes, the cells were washed 3 times and then resuspended in FACS buffer. Fluorescence measurement was performed using a BectonDickinson FACS Canto II-HTS device. The data were analyzed using Graphpad Prism software to obtain the EC of antibody binding to cells. 50 The concentration value is the antibody concentration value corresponding to the maximum fluorescence binding signal of 50% when the B7-H3 antibody and cells overexpressing B7-H3 are combined. The measurement results are shown in Figure 4 .

[0077] Figure 4 The results showed that the antibody B1F1F9G7 of the present invention can bind to B7-H3-293F cells and has an EC equivalent to that of the reference antibody. 50 , and at high antibody concentrations, the antibody has a stronger Bmax (maximum binding signal), which shows that the antibody B1F1F9G7 can bind more to cells that overexpress B7-H3 on their surface.

[0078] Example 4 Detection of endocytic activity of mouse anti-B7-H3 monoclonal antibody

[0079] The DT3C protein can automatically bind to the Fc region of mouse antibodies and further undergo antibody-mediated endocytosis to kill target cells (Yamaguchi M, Nishii Y, Nakamura K, et al. Development of a sensitive screening method for selecting monoclonal antibodies to be internalized by cells [J]. Biochem Biophys Res Commun, 2014, 454 (4): 600-603.). The endocytic activity of anti-B7-H3 antibodies can be quantitatively evaluated by DT3C. The steps are as follows: collect the stable cell line 293F in the logarithmic growth phase that overexpresses human B7-H3 on the surface, centrifuge, discard the supernatant, resuspend in CD05 culture medium (Shanghai Aupumai Biotechnology Co., Ltd., Cat#81075-001), count, and add to the cell plate at 100 μl / well, so that each well has 4×10 3 cells and cultured them at 5% CO2 and 37°C for 24 hours. The next day, dilute the antibody and toxin (DT3C-His) with CD05 to a working concentration of 10 μg / ml. Mix the prepared antibody and toxin in a 1:1 ratio and incubate at room temperature for 30 minutes. After gradient dilution of the mixed solution at the end of incubation, add it to the cell plate at 100 μl / well and culture it at 5% CO2 and 37°C for 3 days. After the culture is completed, remove the cell plate and add 50 μl / well of CellCounting-Lite 2.0Luminescent CellViability Assay (Vazyme, Cat#DD1101-02) thawed to room temperature. Place it at room temperature away from light for 3-5 minutes, and use Tecan i-control to detect the fluorescence signal value. GraphPad Prism software was used for data processing, and the results are as follows Figure 5 As can be seen from the figure, the antibody of the present invention has a good internalization effect.

[0080] Example 5 DNA cloning and sequencing, sequence analysis of anti-B7-H3 antibodies

[0081] Total RNA was extracted from the hybridoma cells of Example 1 using Trizol reagent (Invitrogen, Cat#15596-018).

[0082] The process is briefly described as follows: 5×10 6Place the cells in a 1.5ml centrifuge tube and remove the supernatant. Add 1ml of Trizol reagent and pipette repeatedly several times, then place at 25℃ for 5 minutes to lyse the cells. Next, add 0.2ml of chloroform solution to each tube, shake vigorously for 15 seconds and place at room temperature for 3 minutes. Then, centrifuge the tube at 12000g for 10 minutes at 4℃, remove the centrifuge tube, pipette the upper aqueous phase solution into a new 1.5ml centrifuge tube, and add 0.4ml of isopropanol to precipitate RNA from the aqueous phase. Manually mix the EP tube and place it at 25℃ for 10 minutes, then centrifuge at 4℃12000g for 10 minutes and discard the supernatant. Add 1ml of 75% ethanol and centrifuge again at 4℃7500rpm for 5 minutes, and discard the supernatant. After the RNA precipitate at the bottom of the tube is dried at room temperature for 10 minutes, add 30-50ul of sterile DEPC-treated water to dissolve the RNA sample.

[0083] Next, a reverse transcription cDNA kit (Taraka, Cat#6110A) was used to synthesize the first-strand cDNA with total RNA. The experimental system was prepared as follows: 5 μl of total RNA + 0.5 μl Oligo (dT) + 8.5 μl RNase-free water (a total of 14 μl) was first incubated at 65°C for 5 minutes, and then placed on ice for 2 minutes. Further, 4 μl of 5× buffer + 1 μl of dNTP mixture + 0.5 μl of RNase inhibitor + 1 μl of reverse transcriptase RTase (a total of 20.5 μl system) was added, mixed, incubated at 40°C for 50 minutes, and then incubated at 70°C for 10 minutes to complete cDNA synthesis. The cDNA was further added with poly-G at the 3' end. The reaction system was prepared as follows: 5μl of cDNA sample + 33.5μl of ddH2O + 5μl of 10×TdT buffer + 5μl of CoCl2 + 1μl of dGTP + 0.5μl of terminal deoxynucleotidyl transferase TdT (total volume 50ul), incubated at 37°C for 30 minutes, and then incubated at 70°C for 10 minutes to complete the poly-G tailing.

[0084] Further, the tailed cDNA was used as a template for gene amplification of the variable region of the antibody. For amplifying the variable region sequence of the antibody heavy chain, the PCR reaction system was prepared: 10×Taq enzyme buffer 5μl + universal poly C primer (forward primer) 0.5μl + mouse IgG1 reverse primer 0.5μl + dNTP 1μl + Taq polymerase 1μl + cDNA 1μl + ddH2O 41μl. For amplifying the variable region sequence of the antibody light chain, the PCR reaction system was prepared: 10×Taq enzyme buffer 5μl + universal poly C primer (forward primer) 0.5μl + mouse IgG kappa chain reverse primer 0.5μl + dNTP 1μl + Taq polymerase 1μl + cDNA 1μl + ddH2O 41μl. The temperature cycle for PCR amplification of the antibody heavy chain and light chain variable regions is as follows (steps 2 to 4 are repeated for 25 cycles):

[0085] 1) Pre-denaturation at 95°C for 5 min;

[0086] 2) Denaturation at 95°C for 20 seconds;

[0087] 3) Annealing at 56°C for 20 seconds;

[0088] 4) Extension at 72°C for 30 seconds;

[0089] 5) Store at 25°C for 60 min.

[0090] The PCR products were analyzed by 1% agarose gel electrophoresis, and the DNA segments of corresponding sizes were cut out.

[0091] (VH is about 600bp, VK is about 500bp), and DNA is extracted using QIAquick's gel DNA recovery kit (Cat#28704). Briefly described as follows: Weigh the gel, add 3 times the volume of QG buffer to the gel, and then incubate at 50°C for 10 minutes until the gel is completely dissolved. After adding 1 times the volume of isopropanol to mix, the sample is transferred to the QIA purification column and centrifuged at 13000rpm for 1 minute. Add 750μl of PE buffer to the column, and then centrifuge at 13000rpm for 1 minute. Centrifuge again at 13000rpm to remove residual liquid in the column. Add 30μl of water and centrifuge at 13000rpm for 1 minute to elute, and obtain the prepared DNA sample. The purified PCR product is sequenced to obtain the variable region sequence of the antibody.

[0092] The sequence information of the clones of the present invention is shown in Tables 2 to 4.

[0093] Table 2. Sequence information of anti-B7-H3 antibodies

[0094]

[0095]

[0096] NA: nucleotide; AA: amino acid.

[0097] Table 3. Amino acid sequences of anti-B7-H3 antibodies

[0098]

[0099]

[0100] Table 4. Nucleotide sequences of anti-B7-H3 antibodies

[0101]

[0102]

[0103]

[0104] Enoblituzumab heavy chain amino acid sequence:

[0105] EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYIS

[0106] SDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIY

[0107] YGSRLDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP

[0108] EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH

[0109] KPSNTKVDKRVEPKSCDKTHTCPPCPAPELVGGPSVFLLPPKPKDTLMISRTPE

[0110] VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPPEEQYNSTLRVVSVLTVL

[0111] HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN

[0112] QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPLVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:21)

[0113] Enoblituzumab light chain amino acid sequence:

[0114] DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASY

[0115] RYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK

[0116] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS

[0117] QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:22)

[0118] In summary, the anti-B7-H3 antibody (B1F1F9G7) prepared by the present invention has a stronger affinity for human B7-H3 antigen than the reference antibody, and has an EC value comparable to that of the control antibody. 50 It binds to cynomolgus monkey B7-H3 with Bmax and has strong antibody endocytosis activity. It is a new anti-B7-H3 antibody.

[0119] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A high-affinity anti-B7-H3 monoclonal antibody, characterized in that: The antibody comprises a heavy chain variable region and a light chain variable region; The heavy chain variable region comprises V H CDR1, V H CDR2 and V H CDR3, the light chain variable region comprises V L CDR1, V L CDR2 and V L CDR3; The V H The amino acid sequence of CDR1 is shown in SEQ ID NO: 2; The V H The amino acid sequence of CDR2 is shown in SEQ ID NO: 4; The V H The amino acid sequence of CDR3 is shown in SEQ ID NO: 6; The V L The amino acid sequence of CDR1 is shown in SEQ ID NO: 12; The V L The amino acid sequence of CDR2 is shown in SEQ ID NO: 14; The V L The amino acid sequence of CDR3 is shown in SEQ ID NO:

16.

2. A high-affinity anti-B7-H3 monoclonal antibody according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:8; the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

18.

3. A high-affinity anti-B7-H3 monoclonal antibody according to claim 1, characterized in that: The heavy chain amino acid sequence is shown in SEQ ID NO: 10; the light chain amino acid sequence is shown in SEQ ID NO:

20.

4. A nucleotide molecule, characterized in that The nucleotide molecule encodes the high-affinity anti-B7-H3 monoclonal antibody according to any one of claims 1 to 3.

5. The nucleotide molecule according to claim 4, characterized in that The sequence of the nucleotide molecule is selected from SEQ ID NO: 7 and SEQ ID NO: 17; The sequence SEQ ID NO: 7 encodes the heavy chain variable region of the antibody; The sequence SEQ ID NO: 17 encodes the light chain variable region of the antibody.

6. An expression vector, characterized in that: The expression vector contains the nucleotide molecule according to claim 4 or 5.

7. A host cell, characterized in that The host cell contains the expression vector according to claim 6.

8. The method for preparing a high-affinity anti-B7-H3 monoclonal antibody according to any one of claims 1 to 3, characterized in that: The following steps are included: Preparing an expression vector containing a nucleotide molecule for expressing the high-affinity anti-B7-H3 monoclonal antibody according to any one of claims 1 to 3; The obtained expression vector is transfected into eukaryotic host cells and cultured; The anti-B7-H3 monoclonal antibody was isolated and purified.

9. A bispecific molecule, an antibody immunoconjugate, a chimeric antigen receptor or a pharmaceutical composition comprising the high affinity anti-B7-H3 monoclonal antibody according to any one of claims 1 to 3.

10. Use of the high-affinity anti-B7-H3 monoclonal antibody according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.